These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20954235)

  • 1. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1.
    Cossu F; Malvezzi F; Canevari G; Mastrangelo E; Lecis D; Delia D; Seneci P; Scolastico C; Bolognesi M; Milani M
    Protein Sci; 2010 Dec; 19(12):2418-29. PubMed ID: 20954235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
    Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
    Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
    ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic.
    Cossu F; Milani M; Vachette P; Malvezzi F; Grassi S; Lecis D; Delia D; Drago C; Seneci P; Bolognesi M; Mastrangelo E
    PLoS One; 2012; 7(11):e49527. PubMed ID: 23166698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
    Sun H; Lu J; Liu L; Yang CY; Wang S
    ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for bivalent Smac-mimetics recognition in the IAP protein family.
    Cossu F; Milani M; Mastrangelo E; Vachette P; Servida F; Lecis D; Canevari G; Delia D; Drago C; Rizzo V; Manzoni L; Seneci P; Scolastico C; Bolognesi M
    J Mol Biol; 2009 Sep; 392(3):630-44. PubMed ID: 19393243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.
    Balakrishnan K; Fu M; Onida F; Wierda WG; Keating MJ; Gandhi V
    Oncotarget; 2016 Jun; 7(26):39458-39472. PubMed ID: 27223062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
    Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
    J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
    Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
    Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists.
    Łupicka-Słowik A; Psurski M; Grzywa R; Cuprych M; Ciekot J; Goldeman W; Wojaczyńska E; Wojaczyński J; Oleksyszyn J; Sieńczyk M
    Invest New Drugs; 2020 Oct; 38(5):1350-1364. PubMed ID: 32270379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of small-molecule Smac mimetics as IAP antagonists.
    Wang S
    Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
    Zhu H; Li Y; Liu Y; Han B
    ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization.
    Feltham R; Bettjeman B; Budhidarmo R; Mace PD; Shirley S; Condon SM; Chunduru SK; McKinlay MA; Vaux DL; Silke J; Day CL
    J Biol Chem; 2011 May; 286(19):17015-28. PubMed ID: 21393245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
    Flygare JA; Beresini M; Budha N; Chan H; Chan IT; Cheeti S; Cohen F; Deshayes K; Doerner K; Eckhardt SG; Elliott LO; Feng B; Franklin MC; Reisner SF; Gazzard L; Halladay J; Hymowitz SG; La H; LoRusso P; Maurer B; Murray L; Plise E; Quan C; Stephan JP; Young SG; Tom J; Tsui V; Um J; Varfolomeev E; Vucic D; Wagner AJ; Wallweber HJ; Wang L; Ware J; Wen Z; Wong H; Wong JM; Wong M; Wong S; Yu R; Zobel K; Fairbrother WJ
    J Med Chem; 2012 May; 55(9):4101-13. PubMed ID: 22413863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases.
    Samuel T; Welsh K; Lober T; Togo SH; Zapata JM; Reed JC
    J Biol Chem; 2006 Jan; 281(2):1080-90. PubMed ID: 16282325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.
    Sun H; Nikolovska-Coleska Z; Lu J; Meagher JL; Yang CY; Qiu S; Tomita Y; Ueda Y; Jiang S; Krajewski K; Roller PP; Stuckey JA; Wang S
    J Am Chem Soc; 2007 Dec; 129(49):15279-94. PubMed ID: 17999504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.